CONTRACT ASSAY SERVICES CONTRACT ASSAY SERVICES FOR STEM AND PROGENITOR CELLS

Similar documents
Characterization of Human MSCs Cultured in MesenCult -XF

PRIME-XV Hematopoietic Cell Basal XSFM

Table of Contents. 2.1 NeuroCult NCFC Assay Kit (Rat) Components Additional Required Reagents Required Equipment...

hpsc Growth Medium DXF Dr. Lorna Whyte

PRIME-XV Cell Therapy Products by

Measurement of Hematopoietic Stem Cell Potency Prior to Transplantation

COMPONENT NAME COMPONENT # QUANTITY STORAGE SHELF LIFE FORMAT RosetteSep Human Hematopoietic Progenitor Cell Enrichment Cocktail

Store at 2-8 C. Do not freeze. Store at 2-8 C. Do not freeze. Store at 2-8 C. Do not freeze.

COMPONENT NAME COMPONENT # QUANTITY STORAGE SHELF LIFE FORMAT RosetteSep Human Progenitor Cell Basic Pre-Enrichment Cocktail

COMPONENT NAME COMPONENT # QUANTITY STORAGE SHELF LIFE FORMAT. Store at 2-8 C. Do not freeze. Store at 2-8 C. Do not freeze.

COMPONENT NAME COMPONENT # QUANTITY STORAGE SHELF LIFE FORMAT. Do not freeze. Store at 2-8 C. Do not freeze. Store at 2-8 C.

PRIME-XV Cell Therapy Products by

Neulasta Fulphila. Neulasta (pegfilgrastim), Fulphila (pegfilgrastim-jmdb) Description

STEMdiff Astrocyte Differentiation Kit and STEMdiff Astrocyte Maturation Kit

Stem Cel s Key Words:

INTESTINAL ORGANOIDS. IntestiCult and STEMdiff Media for Intestinal Organoid Culture. Scientists Helping Scientists

Tissue Engineering. Mesenchymal Stem Cells for. Tissue Engineering

ANNOUNCEMENTS. HW2 is due Thursday 2/4 by 12:00 pm. Office hours: Monday 12:50 1:20 (ECCH 134)

Stem cells and tissue engineering

STEMdiff Mesenchymal Progenitor Kit

enix Stem Cell Toxicity Assays

Stem Cell Services. Driving Innovation for Stem Cell Researchers

Catalog # Product Size PRIME-XV Hematopoietic Cell Basal XSFM 500 ml (liquid) Additional package sizes are available at request

Stem Cell Toxicity Assays

19F MRI cellular tracer preserves the differentiation potential of hematopoietic stem cells. Brooke Helfer, PhD Celsense, Inc Pittsburgh PA

Automated and Standardized Counting of CFU Assays of Human Hematopoietic Cells

Monitoring the Safety of Stem Cell Based Therapeutics in Clinical Trials. Jane Lebkowski Ph.D. ASGCT May 18, 2010

ANAT 3231 Cell Biology Lecture 21 Stem Cells

Myelin Repair Foundation Research Progress Report June 2006-July 2007

Custom processing services

Mid-term review. Recitation5 03/31/2014. Stem Cell Biology and Function W4193 1

Fundamental properties of Stem Cells

STEMdiff Hematopoietic Kit

Banking Human Neural Stem Cells for Clinical Applications. Lisa Fox Director, Cell Process Development & Operations

The Science and Biology of Hematopoietic Stem Cell Potency, Quality and Release Criteria for Transplantation

ReproRNA -OKSGM is a non-integrating, self-replicating RNA-based reprogramming vector for generating induced pluripotent stem (ips)

CELL THERAPY FOR THE TREATMENT OF DAMAGED MYOCARDIUM

Mesenchymal Stem Cells

NPTEL Biotechnology Tissue Engineering. Stem cells

T ECHNICAL MANUAL. Culture of Human Mesenchymal Stem Cells Using MesenCult -XF Medium

Stem Cells, Regenerative Medicine and cgmp (GTP)

Supplemental Information Inventory

UK +44 (0) CH +41 (0) DE +49 (0) US

Mesenchymal Stem Cells

Strategies for Assessment of Immunotoxicology in Preclinical Drug Development

Stem Cells: Introduction and Prospects in Regenerative Medicine.

Neural Stem Cell Characterization Kit

Nucleofector Technology in. Somatic Stem Cell Research. gene transfer begins here

About ATCC. Established partner to global researchers and scientists

Cases of Academic Misconduct. Core Components

BME 177. Engineering stem cells. Gayatri Pal Lecturer Biomolecular Engineering

Guide to Clonetics and Poietics Cell Types

Molecular Medicine. Stem cell therapy Gene therapy. Immunotherapy Other therapies Vaccines. Medical genomics

Molecular Diagnostics OEM and Commercial Supply Services. Your partners for success

The Ultimate Low Cell Binding Surface

The Road to Functional Bioanalysis: Development and Validation of a Cell-Based Assay for Neutralizing Anti-Drug Antibody Analysis

Characteristics. Capable of dividing and renewing themselves for long periods of time (proliferation and renewal)

Cultrex Rat Mesenchymal Stem Cell Growth and Differentiation Products

Culture of human mesenchymal stem cells in Nunc Cell Factory systems

ANAT 2341 Embryology Lecture 18 Stem Cells

Table of Contents 1.0 Introduction Thawing Cells, Plating and Colony Enumeration...2

Stem Cells and Cell Culture Developments Within ThermoFisher Scientific

Outcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL

Hypoxic Preconditioning Strategy for Stem Cell Transplantation Therapy after Ischemic Stroke

Andrew Finnerty General Manager - CCMI

Developing Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013

REIMAGINING DRUG DEVELOPMENT:

Stem Cells Canadian Perspective

Stem Cells & Neurological Disorders. Said Ismail Faculty of Medicine University of Jordan

Stem Cell Uses and FDA Regulation

Sharon Tindle, MS, CQA (ASQ) QA Manager, BMT Tissue Services Mount Sinai Hospital, New York, NY. June 7, 2016

BIOSTATISTICAL METHODS

Lyset BOOST YOUR CELL CULTURE TODAY FOR THE EXPERIMENTS OF TOMORROW

Therapeutic Cell Replacement. Steven McLoon Department of Neuroscience University of Minnesota

Understanding brain diseases from stem cells to clinical trials

Culture and Differentiation of Human Embryonic Stem Cells to Form Specific, Functional Cell Types. NAS June 3, 2010

Determining the Predictive Validity of 3D Models & Achieving Standardization for Preclinical Efficacy Testing

Clinical Policy: Sargramostim (Leukine) Reference Number: CP.CPA.262 Effective Date: Last Review Date: Line of Business: Commercial

Sabrina Jedlicka 9/24/2012. NEUROENGINEERING: Interactions of Neurons and Materials

ATPlite Assay Performance in Human Primary Cells

for SCI: Challenges for Entry and Execution of Phase 1 Clinical Trials Challenges and Opportunities of Cellular Therapeutic Development

DOPA Maturation Media

Mesenchymal Stem/Stromal Cells

Axol Bioscience SNAPSHOT PRESENTATION ELRIG ADVANCES IN CELL BASED SCREENING Zoe Allen, PhD Product Specialist

3.4 DNA sequencing: the Sanger method

Stem Cells and Regenerative Medicine

Asterand Bioscience Strategic Alliances

TaqMan Array Cards. Load 384 reactions accurately in 10 minutes without robotics

1 st Saudi Hematology Research Day 04 March 2016 (Friday), Riyadh Marriot Hotel, 6:00 PM 9:00 PM

Regulatory Issues in Human Subjects Research

Zarxio. Zarxio (filgrastim-sndz) Description

Dec 04, 2013

Supporting information. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo

At the conclusion of this lesson you should be able to:

leading the way in research & development

Lab-on-Chip for Testing Myelotoxic Effect of Drugs and Chemicals

Induced Stem Cells in Research and Therapy of Neuropsychiatric Disorders

colorimetric sandwich ELISA kit datasheet

Human Long-Term Culture-Initiating Cell (LTC-IC) Assays

In Vitro Proliferation and Differentiation of Human Neural Stem and Progenitor Cells Using NeuroCult or NeuroCult -XF

Transcription:

CONTRACT ASSAY SERVICES CONTRACT ASSAY SERVICES FOR STEM AND PROGENITOR CELLS

TABLE OF CONTENTS 3 4 5 6 7 Introduction Hematopoietic Stem and Progenitor Cell Assays Mesenchymal Stem and Progenitor Cell Assays Neural Stem and Progenitor Cell Assays References HELPING MAKE YOUR RESEARCH WORK 2 2

CONTRACT ASSAY SERVICES 15 YEARS OF EXPERIENCE IN STEM CELL BIOLOGY INTRODUCTION STEMCELL Technologies Inc. s Contract Assay Services works with you to develop and perform fl exible custom-designed experiments that meet your unique needs and goals. By harnessing our industry-standard reagents and extensive stem cell biology expertise, you will enhance your ability to determine the potency and safety of compounds earlier in the drug development process, thereby saving valuable time and resources. Our experts have conducted more than 400 studies, and have helped over 80 organizations worldwide with their specifi c research needs. A high failure rate of late stage drug candidates is cost prohibitive. Traditional drug discovery platforms based on in vitro animal, tumor, or genetically-transformed cell lines are often poorly representative of the human condition. Using human primary progenitor cells, we can help you obtain more clinically-relevant data, which may signifi cantly improve your drug candidate s translation into the clinic. Our customized assays using primary cells can help you: Obtain clinically relevant, cost-effective information throughout the drug discovery process Reduce animal testing Determine safety and effi cacy of compounds Assess a compound s effects on proliferation and differentiation of various stem and progenitor cells, including: Hematopoietic stem and progenitor cells Mesenchymal stem and progenitor cells Neural stem and progenitor cells 3 3

HEMATOPOIETIC STEM AND PROGENITOR CELL ASSAYS WITH THESE ASSAYS, WE CAN HELP YOU: Screen for toxic effects of compounds in blood or bone marrow Determine the hematopoietic modulating activity of small molecule compounds Assess hematological parameters and progenitor content in clinical samples OUR VALIDATED 2,6,7 IN VITRO ASSAYS CAN HELP YOU DETERMINE A COMPOUND S INHIBITORY OR STIMULATORY EFFECTS ON HEMATOPOIETIC PROGENITORS. Colony-forming cell (CFC) assays have been shown to be important in the evaluation of potential inhibitory or stimulatory effects of a variety of compounds on hematopoietic 1-10 and mesenchymal 3,9 progenitor cells CFC assays can be used to simultaneously assess proliferation and differentiation of progenitors to determine both IC 50 and IC 90 values Clinical samples such as cord blood units can be used to evaluate functionality of hematopoietic progenitors and to assist with the determination of sample suitability for transplantation FIGURE 1. Determination of IC 50 values for 5-Fluorouracil (5-FU) FIGURE 2. Human bone marrow colonies in the presence of an inhibitory compound % Control Growth 150 100 50 Erythroid = 0.67 μg/ml Myeloid = 0.47 μg/ml 0-2 -1 0 1 2 3 Compound Concentration (μg/ml; log 10 ) Control CFU-GM CFU-GM with inhibitory compound OUR IN VIVO ASSAYS CAN HELP YOU EXAMINE THE EFFECTS OF A COMPOUND ON HEMATOPOIETIC STEM CELL MOBILIZATION AND RECOVERY. Assess hematopoietic stem cell mobilization into the peripheral blood Determine kinetics of hematopoietic progenitor recovery following induction of myelosuppression DID YOU KNOW CFC assays for myeloid progenitors have been validated for the determination of maximum tolerated doses by the European Centre for the Validation of Alternative Methods (ECVAM). Assays for CFU-GM and CFU-Mk have been shown to be predictive of clinical outcomes such as neutropenia 2,6 and thrombocytopenia. 7 4 4

CONTRACT ASSAY SERVICES MESENCHYMAL STEM AND PROGENITOR CELL ASSAYS OUR FUNCTIONAL ASSAYS CAN HELP YOU ASSESS THE EFFECTS OF COMPOUNDS ON MESENCHYMAL STEM AND PROGENITOR CELLS DERIVED FROM HUMAN BONE MARROW OR MOUSE COMPACT BONE. Determine progenitor frequency and proliferative potential Examine overall expansion potential Identify differentiation potential of mesenchymal stem cells into adipose, osteogenic and chondrocyte lineages Colony-Forming Unit - Fibroblast (CFU-F) assays are important for the evaluation of inhibitory or stimulatory effects of a variety of compounds on mesenchymal stem and progenitor cells FIGURE 3. Effects of Doxorubicin on Human CFU-F 100 % of Control Growth 80 60 40 20 0 IC50 = 5.18 μm IC90 = 13.75 μm 0.0 0.5 1.0 1.5 2.0 2.5 Compound Concentration (μm; log 10 )? FIGURE 4. Human bone marrow-derived CFU-F colonies in the presence of an inhibitory compound Control human CFU-F Human CFU-F with inhibitory compound DID YOU KNOW Our facility and procedures are certified to ISO13485:2003. Contracts are performed with controls intended to assure the quality and integrity of the process and data. Such controls may include, but are not limited to, qualified personnel, suitable facilities and equipment, sample and reagent handling and storage, and use of standard operating procedures. Please contact STEMCELL Technologies Contract Assay Services for more information regarding studies performed under independent QA audit. 5 5

NEURAL STEM AND PROGENITOR CELL ASSAYS WE CAN HELP EXAMINE THE EFFECTS OF COMPOUNDS AND ENVIRONMENTAL TOXINS ON PRIMARY NEURAL STEM AND PROGENITOR CELLS. Determine proliferation potential using the Neural Colony-Forming Cell (NCFC) assay, which enables identifi cation and quantifi cation of both neural stem and progenitor cells Assess differentiation potential of neural stem and progenitor cells into neurons, astrocytes and oligodendrocytes FIGURE 5. Assays for neural stem and progenitor cells Primary CNS tissue Primary cells are cultured as neurospheres, 3-dimensional spheres containing neural stem and progenitor cells. Differentiation assays are used to assess the effects of your compound on the potential of neural stem and progenitor cells to differentiate into astrocytes, neurons and oligodendrocytes. Proliferation potential can be quantified using the NCFC Assay. < 0.5 mm 0.5-1 mm 1-1.5 mm > 1.5 mm Larger NCFC colonies (>1.5 mm in size) are formed by neural stem cells; the smaller NCFC colonies are formed by more mature neural progenitors. 120 Mouse neurospheres were dissociated and induced to differentiate. Neurons (red) and astrocytes (green) can be detected using immunofluorescent methods. % Control Growth 100 80 60 40 20 0 Lead (Pb) IC 50 =38 mm 0.5 1.0 1.5 2.0 2.5 3.0 Compound Concentration (mm; log 10 ) Dose response curve and IC 50 for lead in the NCFC Assay 6 6.

CONTRACT ASSAY SERVICES WE ARE COMMITTED TO PROVIDING YOU WITH THE HIGHEST LEVEL OF SERVICE Confi dential consultation with our expert scientifi c staff. Custom-designed studies to meet your specifi c requirements. Studies performed using STEMCELL Technologies industry standard reagents manufactured under ISO13485:2003 guidelines. Studies may be performed under independent QA audit. Thorough and timely reporting of data delivered in a comprehensive report that includes summaries, concise details of experimental design, tabulated data and fi gures, as well as statistical analysis of the data and photographic records. REFERENCES 1. Parent-Massin D, Cell Biol Toxicol 17: 87-94, 2001 2. Pessina A, et al., Toxicol Sci 75: 355-67, 2003 3. Van den Heuvel RL, et al., Cell Biol Toxicol 17: 107-16, 2001 4. Pyatt DW, et al., Mol Pharmacol 57: 512-8, 2000 5. Freund YR, et al., Toxicol Appl Pharmacol 18: 16-26, 2002 6. Casati S, et al., Toxicol In Vitro 17: 69-75, 2003 7. Pessina A, et al., Toxicol In Vitro 23: 194-200, 2009 8. Froquet R, et al., Toxicol In Vitro 15: 691-9, 2001 9. Gribaldo L, et al., Toxicol Sci 58: 96-101, 2000 10. Gonz lez-cid M, et al., Cell Biol Toxicol 16: 235-41, 2000 11. Dal Negro G, et al., Toxicol In Vitro 17: 95-105, 2001 12. Breier JM, et al., Toxicol Sci. 105: 119-33, 2008 13. Louis SA, et al., Stem Cells 4: 988-96, 2008 14. Broxmeyer HE, et al., J Exp Med 201: 1307-18, 2005 15. Short BJ, et al., Blood 100: 62a, 2002 Copyright 2011 by STEMCELL Technologies Inc. All rights reserved including graphics and images. STEMCELL Technologies & Design, STEMCELL Shield Design and CELL EXPERTS (THE) are trademarks of STEMCELL Technologies Inc. 7 7

THE CELL EXPERTS WWW.CONTRACTASSAY.COM TOLL-FREE PHONE 1 800 667 0322 PHONE 1 604 877 0713 TOLL-FREE FAX 1 800 567 2899 FAX 1 604 877 0704 CONTRACTASSAY@STEMCELL.COM FOR FULL CONTACT DETAILS WORLDWIDE VISIT OUR WEBSITE FOR RESEARCH USE ONLY. NOT FOR THERAPEUTIC OR DIAGNOSTIC USE. CATALOG #29950 VERSION 2.0.0 JUNE 2011